AstraZeneca Partners with Algen for $555 Million AI Agreement
AstraZeneca has licensed Algen Biotechnologies' AI-driven gene-editing platform, AlgenBrain, for up to $555 million to develop therapies for immune-related disorders, ...
Tag: Algen
News Summarized. Time Saved. Bite-sized news briefs for busy people. No fluff, just facts.